Morgan Stanley analyst Thomas Wrigglesworth initiated coverage of Novonesis (NVZMY) with an Overweight rating and DKK 577 price target Novonesis is a “high-quality biotech-based growth compounder” with structural end market drivers to sustain above-peer sales growth and margins, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVZMY: